Classification/NN
of/IN
IVS1-10T/NN
-->/TO
C/NN
as/IN
a/DT
polymorphism/NN
of/IN
BRCA1/NN
./.

Mutations/NNS
inactivating/VBG
the/DT
tumor/NN
suppressor/NN
gene/NN
BRCA1/NN
may/MD
be/VB
responsible/JJ
for/IN
disease/NN
for/IN
up/RB
to/TO
80/CD
%/NN
of/IN
familial/JJ
ovarian/JJ
cancer/NN
cases/NNS
./.
=====
In/IN
this/DT
syndrome/NN
,/,
tumorigenesis/NN
classically/RB
initiates/VBZ
from/IN
an/DT
inherited/VBN
mutation/NN
in/IN
one/CD
allele/NN
followed/VBN
by/IN
somatic/JJ
deletion/NN
of/IN
the/DT
normal/JJ
allele/NN
./.
=====
Sequencing/NN
of/IN
BRCA1/NN
amplified/VBN
from/IN
genomic/JJ
DNA/NN
of/IN
lymphocytes/NNS
and/CC
microdissected/VBN
ovarian/JJ
tumor/NN
cells/NNS
of/IN
a/DT
familial/JJ
ovarian/JJ
cancer/NN
patient/NN
revealed/VBD
three/CD
,/,
rare/JJ
heterozygous/NN
DNA/NN
variations/NNS
(/(
2418delA/NN
,/,
233G/NN
-->/TO
A/NN
,/,
and/CC
IVS1-10T/NN
-->/TO
C/NN
)/)
in/IN
both/CC
tumor/NN
and/CC
constitutional/JJ
(/(
lymphocyte/NN
)/)
DNA/NN
./.
=====
Thus/RB
,/,
both/DT
copies/NNS
of/IN
BRCA1/NN
were/VBD
retained/VBN
in/IN
tumor/NN
./.
=====
Haplotype/NN
analysis/NN
of/IN
the/DT
patient/NN
and/CC
four/CD
siblings/NNS
assigned/VBD
2418delA/NN
to/TO
one/CD
copy/NN
of/IN
BRCA1/NN
and/CC
233G/NN
-->/TO
A/NN
and/CC
IVS1-10T/NN
-->/TO
C/NN
to/TO
the/DT
other/JJ
./.
=====
The/DT
DNA/NN
change/NN
,/,
2418delA/NN
,/,
is/VBZ
considered/VBN
a/DT
mutation/NN
that/WDT
inactivated/VBD
one/CD
BRCA1/NN
allele/NN
because/IN
it/PRP
caused/VBD
a/DT
frameshift/NN
and/CC
generation/NN
of/IN
a/DT
premature/JJ
stop/NN
codon/NN
,/,
resulting/VBG
in/IN
synthesis/NN
of/IN
a/DT
truncated/VBN
peptide/NN
as/IN
evidenced/VBN
by/IN
an/DT
in/FW
vitro/FW
protein/NN
truncation/NN
test/NN
./.
=====
The/DT
DNA/NN
variation/NN
,/,
233G/NN
-->/TO
A/NN
,/,
does/VBZ
not/RB
result/VB
in/IN
an/DT
amino/NN
acid/NN
change/NN
,/,
and/CC
is/VBZ
considered/VBN
a/DT
benign/JJ
polymorphism/NN
./.
=====
IVS1-10T/NN
-->/TO
C/NN
is/VBZ
a/DT
unique/JJ
BRCA1/NN
change/NN
that/WDT
occurs/VBZ
in/IN
the/DT
last/JJ
nucleotide/NN
of/IN
a/DT
consensus/NN
sequence/NN
for/IN
a/DT
branch/NN
site/NN
critical/JJ
for/IN
RNA/NN
splicing/NN
./.
=====
Therefore/RB
,/,
we/PRP
investigated/VBD
whether/IN
IVS1-10T/NN
-->/TO
C/NN
deleteriously/RB
affected/VBD
BRCA1/NN
splicing/NN
or/CC
expression/NN
,/,
and/CC
thereby/RB
inactivated/VBD
the/DT
other/JJ
BRCA1/NN
allele/NN
./.
=====
Using/VBG
the/DT
technique/NN
of/IN
reverse/JJ
transcription-polymerase/JJ|NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
with/IN
RNA/NN
isolated/VBN
from/IN
lymphoid/JJ
cell/NN
lines/NNS
of/IN
the/DT
patient/NN
and/CC
of/IN
controls/NNS
,/,
no/DT
evidence/NN
was/VBD
found/VBN
that/IN
IVS1-10TC/NN
abnormally/RB
disrupted/VBD
mRNA/NN
splicing/NN
or/CC
caused/VBD
the/DT
absence/NN
of/IN
BRCA1/NN
mRNA/NN
./.
=====
Thus/RB
,/,
IVS1-10T/NN
-->/TO
C/NN
is/VBZ
not/RB
harmful/JJ
to/TO
BRCA1/NN
function/NN
,/,
and/CC
is/VBZ
classified/VBN
a/DT
benign/JJ
polymorphism/NN
./.
=====
Retention/NN
of/IN
the/DT
normal/JJ
BRCA1/NN
allele/NN
in/IN
the/DT
tumor/NN
with/IN
the/DT
heterozygous/JJ
germline/NN
BRCA1/NN
mutation/NN
,/,
2418delA/NN
,/,
indicated/VBD
that/IN
mutational/JJ
inactivation/NN
of/IN
both/DT
BRCA1/NN
alleles/NNS
was/VBD
not/RB
required/VBN
for/IN
tumorigenesis/NN
./.
=====
It/PRP
is/VBZ
possible/JJ
that/IN
the/DT
normal/JJ
allele/NN
may/MD
be/VB
functionally/RB
inactivated/VBN
by/IN
a/DT
nonmutational/JJ
mechanism/NN
./.